Introduction: The treatment of MBC patients is guided by receptor status, with re-biopsy at relapse recommended to reassess hormone receptor (HR) status. Various treatment options are available for HER2-veMBC, including CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors. The study highlights the importance of determining receptor subtype for guiding treatment choices.Patients and Methods: The GIM 13 AMBRA study is a longitudinal cohort study involving 42 centers in Italy. It includes data from 939 HER2- MBC patients enrolled between May 2015 and September 2020. The study analyzes the impact of HR expression changes on clinical outcomes using Kaplan–Meier survival curves and other statistical methods.Results: Among the 939 patients, 588 were rebiopsied at first relapse. The study found no significant differences in disease-free survival (DFS), progression-free survival (PFS), or overall survival (OS) between patients whose tumors changed molecular subtype and those who did not. However, post-progression survival from first-line treatment (PPS1) was different between the two groups.Discussion: The study confirms the phenomenon of receptor discordance between primary tumors and metastases. It emphasizes the need for re-biopsy in recurrent MBC to guide treatment strategies. The findings align with previous studies and highlight the importance of understanding receptor changes for improving patient outcomes.Conclusions: The GIM 13 AMBRA study provides valuable insights into the impact of molecular subtype changes on survival outcomes in Luminal MBC patients. It underscores the importance of re-biopsy and personalized treatment strategies in managing metastatic breast cancer.
引言：转移性乳腺癌（MBC）患者的治疗以受体状态为指导，建议在复发时进行再次活检以重新评估激素受体（HR）状态。针对HER2阴性MBC有多种治疗选择，包括CDK4/6抑制剂、PARP抑制剂和检查点抑制剂。本研究强调了确定受体亚型对指导治疗选择的重要性。 患者与方法：GIM 13 AMBRA研究是一项在意大利42个中心开展的纵向队列研究，纳入了2015年5月至2020年9月期间登记的939例HER2阴性MBC患者。研究采用Kaplan-Meier生存曲线及其他统计方法，分析HR表达变化对临床结局的影响。 结果：在939例患者中，588例在首次复发时接受了再次活检。研究发现，肿瘤分子亚型发生改变与未改变的患者在无病生存期（DFS）、无进展生存期（PFS）和总生存期（OS）方面均无显著差异。然而，两组患者在一线治疗后的进展后生存期（PPS1）存在差异。 讨论：本研究证实了原发性肿瘤与转移灶之间受体状态不一致的现象，强调了对复发性MBC进行再次活检以指导治疗策略的必要性。这些发现与既往研究一致，凸显了理解受体变化对改善患者预后的重要性。 结论：GIM 13 AMBRA研究为分子亚型变化对Luminal型MBC患者生存结局的影响提供了重要见解，强调了再次活检和个体化治疗策略在转移性乳腺癌管理中的关键作用。
肿瘤(癌症)患者之家